the torch Fall 2016, Issue 3 - Page 17

vaccines consist of cancer-derived Igyarto. “If this initial round of testing specific to a certain receptor apply for a National Institutes of molecules fused to a carrier that is expressed by the dendritic cells. When injected, these reagents are taken up by the dendritic cells, which proves our concept, plans are to Health grant and move into preclinical trials in late 2017.” Baylor Scott & White Health is then activate other immune cells, such committed to performing innovative This type of “off-the-shelf” therapy treatments for breast cancer with the as T cells, to find and kill tumor cells. would be delivered through standard vac cinati o n rou te s su c h a s intradermal/intramuscular injections. Vaccines made at Baylor Institute for research and developing new Celebrating Women Luncheon potential to alter the course of Helping Baylor Scott & White Health – North Texas fight cancer treatments available for future generations. Financial support is continuously Immunology Research (BIIR) that needed for the lab to investigate potentially be used for other types of and to implement clinical trials. target dendritic cells could also cancers and infectious diseases. Dr. Igyarto is currently in the pre- clinical phase of manufacturing and testing. “We are excited by the promising preliminary outcomes,” said Dr. October 20, 2016 more ways to treat breast cancer Where: Hilton Anatole Hotel Contact: Christina Goodman, 214.820.4408, [email protected] October 29, 2016 For more information on breast cancer initiatives, contact Sarah Burdi at 214.820.4721 or [email protected] “In the Celebrating Women Breast Cancer Research Lab, novel immunotherapies are being developed to treat these aggressive tumors. These therapies use a patient’s own immune system to fight cancer cells and are emerging as a powerful alternative to standard chemotherapy and radiation therapy.” DHWI Fun Walk/5K Run Helping Baylor Scott & White Health – North Texas fight diabetes Where: DHWI Headquarters Contact: Kali Bailey, 214.820.7980, [email protected] Visit us at for more information